Comera Life Sciences Holdings, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
12Comera Life Sciences Holdings's Business Model
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
About Comera Life Sciences Holdings
Website: https://comeralifesciences.com
CEO (Chief Executive Officer): Mr. Michael G. Campbell CPA
IPO date: 2020-12-21
Contact
Country: US
Address: 12 Gill Street
City: Woburn
State: MA
Phone: 617 871 2101
Zip Code: 01801
Other
CIK: 0001907685
ISIN: US20037C1080
CUSIP: 20037C108
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
